Related Experiment Video
Updated: Jun 15, 2026
Unveiling Therapeutic Opportunities with Melanoma Patient-derived Organoid Models
Published on: September 6, 2024
The combination of ADI-PEG20 and TRAIL effectively increases cell death in melanoma cell lines
Min You1, Niramol Savaraj, Medhi Wangpaichitr
1Sylverster Comprehensive Cancer Center, University of Miami Miller School of Medicine, 1475 NW 12th Avenue, Miami, FL 33136, USA.
Abstract:
Current treatment for advanced, metastatic melanoma is not very effective, and new modalities are needed. ADI-PEG20 is a drug that specifically targets ASS-negative malignant melanomas while sparing the ASS-expressing normal cells. Although laboratory research and clinical trials showed promising results, there are some ASS-negative cell lines and patients that can develop resistance to this drug. In this report, we combined ADI-PEG20 with another antitumor drug TRAIL to increase the killing of malignant melanoma cells. This combination can greatly inhibit cell growth (to over 80%) and also enhanced cell death (to over 60%) in four melanoma cell lines tested compared with control. We found that ADI-PEG20 could increase the cell surface receptors DR4/5 for TRAIL and that caspase activity correlated with the increased cell death. These two drugs could also increase the level of Noxa while decrease that of survivin. We propose that these two drugs can complement each other by activating the intrinsic and extrinsic apoptosis pathways, thus enhance the killing of melanoma cells.
Insights
This study combined ADI-PEG20 with TRAIL to treat advanced melanoma. The combination significantly inhibited melanoma cell growth and enhanced cell death by activating apoptosis pathways.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Advanced, metastatic melanoma lacks effective treatments.
- ADI-PEG20 targets Argininosuccinate Synthetase (ASS)-negative melanoma but faces resistance.
- Novel therapeutic strategies are crucial for improving patient outcomes.
Purpose of the Study:
- To evaluate the efficacy of combining ADI-PEG20 with TRAIL against malignant melanoma.
- To investigate the underlying molecular mechanisms of the combination therapy.
Main Methods:
- Treatment of four melanoma cell lines with ADI-PEG20 and TRAIL.
- Assessment of cell growth inhibition and cell death.
- Analysis of cell surface receptor expression (DR4/5), caspase activity, and protein levels (Noxa, survivin).
Main Results:
- The combination therapy inhibited cell growth by over 80% and enhanced cell death by over 60%.
- ADI-PEG20 upregulated DR4/5 receptors, sensitizing cells to TRAIL.
- Increased caspase activity, Noxa, and decreased survivin levels were observed, indicating apoptosis induction.
Conclusions:
- Combining ADI-PEG20 with TRAIL offers a promising strategy to overcome resistance and enhance melanoma cell killing.
- The synergistic effect is mediated by the activation of both intrinsic and extrinsic apoptosis pathways.
- This combination therapy warrants further investigation in clinical settings for advanced melanoma.
